On February 7, 2018, Lupin announced positive results from a Phase III clinical trial for its etanercept biosimilar candidate, YB113. YB113 is being developed by YL Biologics, a joint venture of Lupin and Yoshido, a Japanese pharmaceutical company. The clinical trial compared the safety and efficacy of YB113 to Amgen’s Enbrel® (etanercept) in patients with rheumatoid arthritis. According to Lupin, response rates, safety and immunogenicity of YB113 were all found to be similar to Enbrel®, indicating therapeutic equivalence.
